QR-Code

Anakinra for the treatment of COVID-19 patients: a systematic review and meta-analysis

Abstract Background At the end of 2021, the European Medicines Agency (EMA) expanded its approval for the recombinant human interleukin-1 (IL-1) receptor antagonist Anakinra for the treatment of COVID-19 patients with elevated soluble urokinase plasminogen activator receptor (suPAR). However, the ro...

Ausführliche Beschreibung

Gespeichert in:
Hauptverfasser: Karolina Dahms, Agata Mikolajewska, Kelly Ansems, Maria-Inti Metzendorf, Carina Benstoem, Miriam Stegemann
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2023-02-01
Schriftenreihe:European Journal of Medical Research
Schlagworte:
Anakinra
Interleukin 1 receptor antagonist protein
SARS-CoV-2
Hospitalization
Meta-analysis
Systematic review
Online-Zugang:https://doi.org/10.1186/s40001-023-01072-z
Tags: Tag hinzufügen
Keine Tags, Fügen Sie das erste Tag hinzu!

Ähnliche Einträge